epitiostanol: used in therapy of advanced breast cancer; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 443935 |
| CHEMBL ID | 2106161 |
| CHEBI ID | 31546 |
| SCHEMBL ID | 8995 |
| MeSH ID | M0043853 |
| Synonym |
|---|
| nsc-194684 |
| 10275-s |
| nsc 194684 |
| androstan-17-ol, 2,3-epithio-, (2alpha,3alpha,5alpha,17beta)- |
| epitiostanol [inn:jan] |
| 2alpha,3alpha-epithio-5alpha-androstan-17beta-ol |
| 2alpha,3alpha-epithio-5alpha-androstan-17beta-o1 |
| 5alpha-androstan-17beta-ol, 2alpha,3alpha-epithio- |
| epitiostanolum [inn-latin] |
| 2-alpha,3-alpha-epithio-5-alpha-androstan-17-beta-ol |
| NCGC00016609-01 |
| cas-2363-58-8 |
| 2363-58-8 |
| epitiostanol |
| epitiostanol (jan/inn) |
| D01265 |
| unii-ye7586973l |
| ye7586973l , |
| epitiostanolum |
| dtxsid2045367 , |
| dtxcid0025367 |
| tox21_110520 |
| epithioandrostanol |
| CHEMBL2106161 |
| epitiostanol [mi] |
| epitiostanol [mart.] |
| epitiostanol [inn] |
| epitiostanol [who-dd] |
| epitiostanol [jan] |
| CCG-221006 |
| SCHEMBL8995 |
| CHEBI:31546 |
| 2alpha,3alpha-epithio-5alpha-androstane-17beta-ol |
| (1s,2s,4r,6s,8s,11r,12s,15s,16s)-2,16-dimethyl-5-thiapentacyclo[9.7.0.0,.0,.0,octadecan-15-ol |
| (1s,2s,4r,6s,8s,11r,12s,15s,16s)-2,16-dimethyl-5-thiapentacyclo[9.7.0.02,8.04,6.012,16]octadecan-15-ol |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
| Class | Description |
|---|---|
| organic molecular entity | Any molecular entity that contains carbon. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| AR protein | Homo sapiens (human) | Potency | 0.0766 | 0.0002 | 21.2231 | 8,912.5098 | AID743035; AID743036; AID743040; AID743053; AID743054; AID743063 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 1.1837 | 0.0002 | 29.3054 | 16,493.5996 | AID743069; AID743075; AID743077; AID743078; AID743079 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 2.5429 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
| potassium voltage-gated channel subfamily H member 2 isoform d | Homo sapiens (human) | Potency | 7.0795 | 0.0178 | 9.6374 | 44.6684 | AID588834 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 9.0226 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 9 (47.37) | 18.7374 |
| 1990's | 5 (26.32) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (15.79) | 24.3611 |
| 2020's | 2 (10.53) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (24.47) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (5.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 2 (10.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 17 (85.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||